I kliniske undersøgelser forbedrede sitagliptin som monoterapi den glykæmiske kontrol ved signifikant reduktion af hæmoglobin A1c (HbA1c) samt faste - og postprandial glucose.
In clinical trials, sitagliptin as monotherapy improved glycaemic control with significant reductions in haemoglobin A1c (HbA1c) and fasting and postprandial glucose.